Cargando…

Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow

INTRODUCTION: Slow coronary flow (SCF) is an angiographic phenomenon characterized by delayed opacification of epicardial coronary arteries without an obstructive coronary disease. Serum soluble urokinase-type plasminogen activator receptor (suPAR) levels seem closely related to atherosclerosis due...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emrah, Acar, Akın, İzgi İbrahim, Servet, İzci, Muzaffer, Kahyaoğlu, Fatih, Yılmaz Mehmet, Yeliz, Güler, Çağan, Efe Süleyman, Ahmet, Güler, Alev, Kılıçgedik, Cevat, Kırma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421532/ https://www.ncbi.nlm.nih.gov/pubmed/28905020 http://dx.doi.org/10.5114/amsad.2016.60819

Ejemplares similares

Non-O-blood types associated with higher risk of high-grade atrioventricular block
por: Acar, Emrah, et al.
Publicado: (2019)

Saphenous vein graft aneurysm: A case report
por: Gurbuz, Ahmet Seyfeddin, et al.
Publicado: (2016)

Papillary Muscle Free Strain in Patients with Severe Degenerative and Functional Mitral Regurgitation
por: Kılıcgedik, Alev, et al.
Publicado: (2017)

Left Atrial Mechanical Function and Aortic Stiffness in Middle-aged Patients with the First Episode of Atrial Fibrillation
por: Kılıcgedik, Alev, et al.
Publicado: (2017)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Reply to Letter to the Editor: “Single-Stent Double-Kissing Nano-Crush Technique for the Management of Side Branch Ostial Lesions: A Game Changer? Or Just Another Player in the Game?”
por: Acar, Emrah, et al.
Publicado: (2023)

Reply to Letter to the Editor: “Pros and Cons of a Novel Coronary Stenting Technique for Medina 0.0.1 Lesions: Osdokina Crush”
por: Acar, Emrah, et al.
Publicado: (2023)

One-Stent Double-Kissing Nano Crush—Osdokina Crush—Technique Could be a Game-Changer in the Treatment of Medina 0.0.1 Lesion
por: Acar, Emrah, et al.
Publicado: (2023)

Closure of mitral paravalvular defects without performing an arteriovenous loop: a case series of fourteen patients
por: Kilicgedik, Alev, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
por: Höybye, Charlotte, et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases
por: Manfredi, Mariangela, et al.
Publicado: (2023)

Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters
por: Ventorp, Filip, et al.
Publicado: (2015)

A Pushed Descending Aorta due to Hiatal Hernia
por: Gecmen, Cetin, et al.
Publicado: (2019)

The Clinical Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels in Autoimmune Connective Tissue Disorders
por: Vasarhelyi, Barna, et al.
Publicado: (2016)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients
por: Torino, Claudia, et al.
Publicado: (2018)

Evaluation of soluble urokinase-type plasminogen activator receptor (suPAR) quick test for triage in the emergency department
por: Kumar, Pratyush, et al.
Publicado: (2019)

Comparison of the Mortality Prediction Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in COVID-19 and Sepsis
por: Vassiliou, Alice G., et al.
Publicado: (2022)

Relationship Between Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Disease Outcome in Adult-Onset Asthma
por: Niemelä, Taito, et al.
Publicado: (2022)

Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience
por: Infantino, Maria, et al.
Publicado: (2022)

Serum Levels of Urokinase Plasminogen Activator Receptor (suPAR) Discriminate Moderate Uncontrolled from Severe Asthma
por: Kotsiou, Ourania S., et al.
Publicado: (2022)

Relationship of Circulating Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels to Disease Control in Asthma and Asthmatic Pregnancy
por: Ivancsó, István, et al.
Publicado: (2013)

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
por: Lee, Jiwon M., et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Independently Predicts Severity and Length of Hospitalisation in Patients With COVID-19
por: Enocsson, Helena, et al.
Publicado: (2021)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Emergency Department (Ed): A Tool for the Assessment of Elderly Patients
por: Holstein, Ria M., et al.
Publicado: (2022)

Enlargement Ratio May Predict Device Size in Elderly Patients with Atrial Septal Defect
por: Ozturk, Semi, et al.
Publicado: (2017)

Thrombus aspiration during primary percutaneous coronary intervention associated with reduced platelet activation
por: Sahin, Muslum, et al.
Publicado: (2015)

Multimodality Imaging of Large Left Ventricular Apical Pseudoaneurysm after Thoracic Surgery
por: Çiçek, Mahmut Buğrahan, et al.
Publicado: (2020)

Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases
por: Loosen, Sven H., et al.
Publicado: (2018)

The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine
por: Scharrenberg, Jan Simon, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
por: Rovina, Nikoletta, et al.
Publicado: (2020)

Evaluation of the P Wave Axis in Patients With Systemic Lupus Erythematosus
por: Acar, Rezzan Deniz, et al.
Publicado: (2015)

Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) and Impaired Kidney Function in the Population-based Malmö Diet and Cancer Study
por: Schulz, Christina-Alexandra, et al.
Publicado: (2016)

Sex Differences in Circulating Soluble Urokinase‐Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease
por: Mehta, Anurag, et al.
Publicado: (2020)

Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method
por: Winnicki, Wolfgang, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit
por: Reisinger, Alexander C., et al.
Publicado: (2021)

Soluble urokinase-type plasminogen activator receptor (suPAR) is a risk indicator for eGFR loss in kidney transplant recipients
por: Jehn, Ulrich, et al.
Publicado: (2021)

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_97oo4p7abi26qg2krim1gpdqer